Sign in

Chris Vachowski

Research Analyst at Private Investor

Chris Vachowski is an independent analyst and private investor specializing in small-cap medical device and precision optics companies, with a recent focus on Precision Optics Corporation and related aerospace backlog and medical device programs. He is recognized for his in-depth financial analysis and probing questions on earnings calls, notably addressing revenue, gross margins, and operational efficiency, but public records do not attribute a published performance track record, platform ranking, or specific return metrics to his investment recommendations. Vachowski operates as a private investor with no publicly disclosed affiliations to major sell-side or buy-side firms, and his career history as an analyst is not tracked through industry-standard databases or FINRA registrations. While regarded as a knowledgeable participant in corporate calls, there is no verification of securities licenses or formal recognition by industry bodies.

Chris Vachowski's questions to PRECISION OPTICS CORPORATION (POCI) leadership

Question · Q4 2025

Chris Vachowski inquired about Precision Optics Corporation's conservative revenue guidance for fiscal year 2026, especially given expected increases from major customers and engineering revenues. He also asked about the company's ability to charge capital costs to customers, the renegotiated pricing and tariff reimbursements for the medical program, the current status of engineering resource allocation, and the potential impact of past engineering resource deployment on future production orders.

Answer

Joseph Forkey, CEO & President, Precision Optics Corporation, explained that the guidance is slightly conservative due to an expected $800,000 decrease in micro-optics lab revenue from a timing-related order and a shift from lower-margin tooling/fixturing revenue to higher-margin production revenue. He confirmed the ability to charge capital costs with a small, low-risk markup. For the medical program, he detailed that the customer agreed to higher near-term pricing to cover startup costs, with a negotiated step-down schedule to original margins, and verbal agreements are in place for tariff reimbursements. He clarified that while some engineering is still needed for product redesigns to improve yields, the need for engineers on the production line has substantially decreased due to new hires and process improvements, freeing up resources for new product development. He also noted that the engineering pipeline is robust, with several programs nearing production and new programs being onboarded, mitigating concerns about past resource allocation impacting future production orders.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts